Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 26, 2003

View Archived Issues

GSK-3beta negatively regulates normal cardiac growth and systolic function in transgenic mice

Avant to conduct phase II trial of TP-10 in women

Accelerated development of viral inhibitor Thiovir for HIV

Beneficial effects of eplerenone in AMI patients with low LVEF

Cytochroma selects drug candidate for treatment of psoriasis

Conivaptan effects on exercise tolerance in patients with chronic heart failure

Clinical trials of MB-7133 begin in liver cancer

Tezosentan: effects on BNP and hemodynamics in acute decompensated heart failure

Carvedilol safe and effective in heart failure patients with Chagas' disease

NSAID + sumatriptan more effective than other therapies for migraine

Sustained pain relief described for subcutaneous DHE in migraine

Daptomycin equieffective to vancomycin and semisynthetic penicillin in skin infections

Phase II results reported for tigecycline in patients with skin and abdominal infections

NicOx to reacquire CINOD rights

Phase II clinical trial of ProCord for spinal cord injury

French authorities recommend against approval of Remodulin

New antiallergic/antiasthmatic agents developed at Rigel

Kissei patents new thyroid hormone receptor ligands

Novel TF/factor VIIa inhibitors under study at Roche

Elan researchers present novel gamma-secretase inhibitors

Indole-based alpha1A-adrenoceptor agonists for urinary incontinence and other uses

Ono scientists prepare and test novel PDE7 inhibitors

Name change for Myriad Proteomics

EluSys receives additional U.S. Department of Defense funds to further develop anthrax drug

Namenda recommended for approval for Alzheimer's disease

Teva and Acorda collaborate on valrocemide

Watson and UCB enter marketing and supply agreement on Oxytrol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal
BioWorld
Beone Medicines Ltd. gained an exclusive option to develop cancer immunotherapy HH-160 worldwide in a deal potentially worth more than $2 billion for Huahui...
Unique trial strategy muddies the ODAC waters for camizestrant
BioWorld
Following a discussion that focused more on a new personalized trial strategy rather than the proposed therapy, the U.S. FDA’s Oncologic Drugs Advisory Committee...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...